<DOC>
	<DOC>NCT00310674</DOC>
	<brief_summary>Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 months of age</brief_summary>
	<brief_title>Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy children of 11 to 15 weeks of age Children who previously received any kind of Meningococcal C vaccine, DTaPIPVHBVHib vaccine or a Hepatitis B vaccine at birth Children who have a previous ascertained or suspected disease caused by N. meningitidis, Corynebacterium diphtheriae, Clostridium tetani, poliovirus, Hepatitis B or H. influenzae type b, culture proven Bordetella pertussis, or clinical condition of spasmodic cough for a period longer than or equal to 2 weeks associated with apnea or whooping Children who have had household contact with and/or intimate exposure to an individual with culture proven N. meningitidis serogroup C or Bordetella pertussis, within the previous 60 days</criteria>
	<gender>All</gender>
	<minimum_age>11 Weeks</minimum_age>
	<maximum_age>15 Weeks</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Prevention of Meningococcal Meningitis</keyword>
	<keyword>meningococcal vaccines</keyword>
	<keyword>conjugate</keyword>
	<keyword>Immunology</keyword>
	<keyword>infant</keyword>
</DOC>